Advertisement

Original nootropic drug Noopept prevents memory deficit in rats with muscarinic and nicotinic receptor blockade

  • K. S. Radionova
  • A. P. Belnik
  • R. U. Ostrovskaya
Pharmacology and Toxicology

Antiamnesic activity of Noopept was studied on the original three-way model of conditioned passive avoidance response, which allows studying spatial component of memory. Cholinoceptor antagonists of both types (scopolamine and mecamylamine) decreased entry latency and reduced the probability for selection of the safe compartment. Noopept abolished the antiamnesic effect of cholinoceptor antagonists and improved spatial preference.

Key Words

Noopept three-way model of conditioned passive avoidance response cholinergic transmission deficit spatial memory antiamnesic properties 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    A. P. Belnik, R. U. Ostrovskaya, and I. I. Poletaeva, Byull. Eksp. Biol. Med., 143, No. 4, 407–410 (2007).CrossRefGoogle Scholar
  2. 2.
    A. N. Inozemtsev, A. P. Belnik, and R. U. Ostrovskaya, Eksper. Klin. Farmakol., 70, No. 3, 67–69 (2007).Google Scholar
  3. 3.
    R. U. Ostrovskaya, T. Kh. Mirzoev, F. A. Firova, et al., Ibid., 64, No. 2, 11–14 (2001).Google Scholar
  4. 4.
    R. U. Ostrovskaya, T. A. Gudasheva, T. A. Voronina, and S. B. Seredenin, Ibid., 65, No. 5, 66–72 (2002).Google Scholar
  5. 5.
    K. S. Us, V. A. Kraineva, I. P. Galaeva, et al., Psikhofarmakol. Biol. Narkol., 6, Nos. 1–2, 1156–1164 (2006).Google Scholar
  6. 6.
    G. Fricker and J. Drewe, J. Pept. Sci., 2, No. 4, 195–211 (1996).PubMedGoogle Scholar
  7. 7.
    G. Gron, I. Brandenburg, A. P. Wunderlich, and M. W. Riepe, Neurobiol. Aging, 27, No. 1, 78–87 (2006).PubMedCrossRefGoogle Scholar
  8. 8.
    T. A. Gudasheva, T. A. Voronina, et al., Eur. J. Med. Chem., 31, 151–157 (1996).CrossRefGoogle Scholar
  9. 9.
    A. D. Lawrence and B. J. Sahakian, Neurochem. Res., 23, No. 5, 787–794 (1998).PubMedCrossRefGoogle Scholar
  10. 10.
    L. Leblond, C. Beaufort, F. Delerue, and T. P. Durkin, Behav. Brain Res., 128, No. 1, 91–102 (2002).PubMedCrossRefGoogle Scholar
  11. 11.
    K. Maubach, Expert Opin. Investig. Drugs, 12, No. 9, 1571–1575 (2003).PubMedCrossRefGoogle Scholar
  12. 12.
    R. U. Ostrovskaya, T. A. Gudasheva, S. S. Trofimov, et al., Biological Basis of Individual Sensitivity to Psychotropic Drugs, Eds. S. B. Seredenin et al., Edinburgh (1994), pp. 79–91.Google Scholar
  13. 13.
    R. U. Ostrovskaya, M. A. Gruden, N. A. Bobkova, et al., J. Psychopharmacol., 21, No. 6, 611–619 (2007).PubMedCrossRefGoogle Scholar
  14. 14.
    D. S. Reddy, Methods Find. Exp. Clin. Pharmacol., 20, No. 3, 249–277 (1998).PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2008

Authors and Affiliations

  • K. S. Radionova
    • 1
  • A. P. Belnik
    • 1
  • R. U. Ostrovskaya
    • 1
  1. 1.V. V. Zakusov Institute of PharmacologyRussian Academy of Medical SciencesMoscowRussia

Personalised recommendations